Cyclosporin-A (CsA) therapeutic drug monitoring plays an integral role
in therapeutic management of immunosuppressed patients, including tho
se with organ transplants. This communication, prepared by an Australi
an team, presents recommendations for the routine monitoring of CsA, i
ncluding blood sampling methodological approaches and interpretation o
f results generated. The consensus approach described is intended to a
ddress the diversity of attitudes to CsA monitoring demonstrated in a
recent national survey of Australian laboratories that provide CsA ana
lyses.